BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...other CRISPR-edited allogeneic CAR T programs in the clinic: BCMA-targeting CTX120 for multiple myeloma and CD70-targeting...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...abated following the June readout.J&J is partnered separately with argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) to develop CD70-targeting...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...company is planning to submit an IND for its third TRuC T cell therapy targeting CD70...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...I study of 12 AML patients with a median age of 75, monotherapy with the anti-CD70...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...programs are based on the biotech’s TriMix technology, which combines therapeutic mRNA molecules that encode CD70...
...and financial terms were still being finalized. Targets CD40L (CD40LG; CD154) - CD40 ligand CD70 (CD27L...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

...either CR or CR with incomplete hematologic recovery. J&J gained rights to the mAb against CD70...
...argenx received $500 million up front (see “argenx gets $500M up front from Janssen for CD70...
...2 c-Kit (KIT; CD117) - Stem cell factor (SCF) receptor tyrosine kinase CD33 (SIGLEC3) CD70 (CD27L...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...S.A. Programmed cell death 1 (PD-1) (PDCD1) (CD279) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) CD70 (CD27L) Splice...
BioCentury | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

...argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to Phase I/II anti-CD70...
BioCentury | Dec 12, 2019
Company News

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

...& Johnson (NYSE:JNJ) unit paid $500 million up front for exclusive, worldwide rights to the anti-CD70...
Items per page:
1 - 10 of 94